A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
Completed · Phase 4
Conditions studied: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
In brief
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Key facts
- Study ID
- NCT00327691
- Run by
- Pfizer
- People needed
- 8600
- Starts
- 1998-04-01
- Expected to finish
- 2004-08-01
- Last updated by the study team
- 2007-05-03
Who can join
Age: 35 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men and women age 35-75 who have evident CHD
You may not qualify if…
- Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia
Where it is running
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Hoover, Alabama, United States
- Pfizer Investigational Site — Montgomery, Alabama, United States
- Pfizer Investigational Site — Mesa, Arizona, United States
- Pfizer Investigational Site — Mesa, Arizona, United States
- Pfizer Investigational Site — Burbank, California, United States
- Pfizer Investigational Site — Camp Pendleton, California, United States
- Pfizer Investigational Site — Fresno, California, United States
- Pfizer Investigational Site — La Jolla, California, United States
- Pfizer Investigational Site — Loma Linda, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Modesto, California, United States
- Pfizer Investigational Site — Pasadena, California, United States
- Pfizer Investigational Site — Rancho Mirage, California, United States
- Pfizer Investigational Site — San Diego, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — Santa Rosa, California, United States
- Pfizer Investigational Site — Stanford, California, United States
- Pfizer Investigational Site — Aurora, Colorado, United States
- Pfizer Investigational Site — Denver, Colorado, United States
- Pfizer Investigational Site — Alabaster, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.